Bausch Health Companies Inc. (BHC) 2018 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, and welcome to the Bausch Health Third Quarter 2018 Earnings Conference Call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Art Shannon, Senior Vice President, Head of Investor Relations and Global Communications. Please go ahead.

    早安,歡迎參加 Bausch Health 2018 年第三季財報電話會議。(接線員指示) 請注意,本活動將被錄音。現在我想將會議交給投資人關係與全球傳播資深副總裁兼主管 Art Shannon。請開始。

  • Arthur J. Shannon - Senior VP and Head of IR & Communications

    Arthur J. Shannon - Senior VP and Head of IR & Communications

  • Thank you, Chad. Good morning, everyone, and welcome to our Third Quarter 2018 Financial Results Conference Call. Participating on today's call are Chairman and Chief Executive Officer, Mr. Joe Papa; and Chief Financial Officer, Mr. Paul Herendeen. In addition to this live webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.

    謝謝你,Chad。各位早安,歡迎參加我們 2018 年第三季財務結果電話會議。今天參與會議的有董事長兼執行長 Joe Papa 先生,以及財務長 Paul Herendeen 先生。除本次即時網路直播外,今日簡報投影片的副本以及本次電話會議的重播,將可於我們網站「投資人關係」專區取得。

  • Before we begin, we'd like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of the presentation as it contains important information.

    在開始之前,我們想提醒各位,今天的簡報包含前瞻性資訊。請各位花點時間閱讀簡報開頭的前瞻性聲明說明,當中包含重要資訊。

  • This presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix of the presentation posted on our website.

    本簡報包含非 GAAP 財務衡量指標。關於這些衡量指標的更多資訊,請參閱簡報第 2 頁投影片。非 GAAP 調節表可於我們網站所發布之簡報附錄中查閱。

  • Finally, the financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter and not to update or affirm guidance other than through broadly disseminated public disclosure.

    最後,本簡報中的財務指引僅以今日為準。我們的政策通常是在下一季之前不更新指引,且除透過廣泛發布的公開揭露外,不會更新或確認指引。

  • With that, it's my pleasure to turn the call over to Joe.

    接下來,我很榮幸將電話會議交給 Joe。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Thank you, Art, and thanks, everyone, on the phone for joining us this morning. Let's quickly review the topic for today's call. I'll begin with the third quarter highlights before turning the call over to Paul Herendeen, our CFO, to review the financial results in detail and update our 2018 guidance. I then will review the segment highlights and catalysts before opening the line for questions.

    謝謝你,Art,也謝謝今天早上加入電話會議的各位。讓我們快速回顧今天電話會議的議程。我將先說明第三季重點,接著把電話交給我們的財務長 Paul Herendeen,詳細說明財務結果並更新 2018 年指引。之後我會回顧各事業部門的重點與催化因素,最後開放提問。

  • Beginning on Slide 4. I'm pleased to say the third quarter results further demonstrate that our progress towards transformation is on track. In addition to another consecutive of overall organic growth, we successfully delivered organic growth across all reporting segments and generated great cash flow from operations in the third quarter. Based on the efforts of the 21,000-plus Bausch Health team members around the world, we are executing on our plans to resolve legacy issues, investing in core franchises and launching new products that we expect to be the foundation of our future growth.

    從第 4 頁投影片開始。我很高興地表示,第三季的結果進一步證明我們朝向轉型的進展如期推進。除了整體有機成長再度連續一季之外,我們也成功在所有申報部門實現有機成長,並於第三季創造了優異的營運現金流。憑藉全球超過 21,000 名 Bausch Health 團隊成員的努力,我們正執行計畫以解決歷史遺留問題、投資核心事業並推出新產品,我們預期這些將成為未來成長的基礎。

  • On Slide 5, we've called out some of the highlights that demonstrate our continued progress towards transformation. First and foremost, our businesses are growing. Revenue grew organically by 3% compared to the prior year quarter, and third quarter 2018 was our third consecutive quarter of overall organic revenue growth. We also generated $522 million of cash from operations in the third quarter.

    在第 5 頁投影片中,我們列出一些重點,展現我們持續朝轉型邁進的進展。首先也是最重要的,我們的業務正在成長。營收較去年同期有機成長 3%,而 2018 年第三季是我們整體有機營收連續第三季成長。我們在第三季也創造了 5.22 億美元的營運現金流。

  • At the product level, our top 10 products grew organically by 7% in the aggregate compared to the prior year quarter.

    在產品層面,我們前 10 大產品合計較去年同期有機成長 7%。

  • Moving on to the top right of Slide 5, we had a lot of new product activity, including the launches of LUCEMYRA in August, the SiHy Daily lenses, which were launched in Japan in September; and PLENVU, which was also launched in September. I'll cover a few other recent and upcoming launches in more detail later in the call.

    接著看第 5 頁投影片右上角,我們有許多新產品動態,包括 8 月推出 LUCEMYRA、9 月在日本推出 SiHy Daily 鏡片,以及同樣於 9 月推出 PLENVU。我會在稍後的電話會議中更詳細說明其他近期及即將推出的產品。

  • Moving to the bottom left, I'm delighted to say that as of today, we have reduced debt by approximately $7.4 billion since the first quarter of 2016, bringing total debt below $25 billion. This included more than $360 million of debt repaid from cash generated from operations during the third quarter.

    再看左下角,我很高興地表示,截至今日,我們自 2016 年第一季以來已將債務減少約 74 億美元,使總債務降至 250 億美元以下。其中包括第三季以營運產生的現金償還超過 3.6 億美元的債務。

  • Finally, thanks to the hard work of our legal team, we resolved approximately 60 matters since January 1, 2018. Notably, we resolved the XIFAXAN intellectual property litigation, which we expect will preserve market exclusivity until 2028 without making any financial payments.

    最後,感謝法務團隊的辛勤努力,我們自 2018 年 1 月 1 日以來已解決約 60 件事項。值得一提的是,我們解決了 XIFAXAN 智慧財產權訴訟,我們預期可在不支付任何金錢的情況下,將市場獨占性維持至 2028 年。

  • We also resolved the legacy Salix SEC investigation without any monetary penalty. We have also resolved the outstanding arbitration with Alfasigma and picked up a late-stage Rifaximin development project.

    我們也在未遭任何金錢處罰的情況下,解決了 Salix 過往的 SEC 調查。我們亦已解決與 Alfasigma 的未決仲裁,並取得一項後期階段的 Rifaximin 開發專案。

  • On Slide 6, we present a snapshot of key third quarter financial highlights for our 4 segments. Approximately 75% of our total third quarter revenue was generated by the Bausch + Lomb/International and the Salix segments. On a combined basis, these segments grew organically by 3% during the third quarter compared to the third quarter 2017. As I mentioned earlier, third quarter '18 was the first quarter that all 4 of our segments grew organically: Bausch + Lomb/International by 3%; Salix by 2%, despite the serious loss of exclusivity during the quarter; Ortho Dermatologics grew by 1%; and Diversified Products by 4%.

    在第 6 頁投影片中,我們呈現四個部門第三季關鍵財務重點的概覽。我們第三季總營收約 75% 來自 Bausch + Lomb/International 與 Salix 兩個部門。合併計算,這兩個部門在第三季相較 2017 年第三季有機成長 3%。如我先前提到,2018 年第三季是我們四個部門首次全部實現有機成長:Bausch + Lomb/International 成長 3%;Salix 成長 2%,儘管該季面臨嚴重的獨占權到期(LOE);Ortho Dermatologics 成長 1%;Diversified Products 成長 4%。

  • In summary, it was a strong quarter across the board.

    總結而言,這是一個各方面表現強勁的季度。

  • With that, I'll turn it over to Paul to take you through the financial results in further detail.

    接下來,我把時間交給 Paul,帶各位更深入了解財務結果。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Thanks, Joe. I'll start by walking down the P&L slide on Slide 7. As Joe said, strong quarter, revenue was 3% organically from Q3 of '17 and adjusted EBITDA was up 5% organically. All 4 of our segments delivered organic revenue growth.

    謝謝你,Joe。我將先從第 7 頁投影片的損益表(P&L)開始說明。如 Joe 所說,本季表現強勁,營收相較 2017 年第三季有機成長 3%,調整後 EBITDA 有機成長 5%。我們四個部門全數實現有機營收成長。

  • Walking down the P&L, providing a little color with respect to the key line items. I just, first, want to point out that when we talk about organic growth, that means on a constant-currency basis adjusted by divestitures and discontinuations.

    接著沿著損益表往下說明,並就關鍵科目補充一些背景。我首先想指出,當我們談到有機成長,指的是以固定匯率基礎,並就資產出售與停業項目進行調整後的結果。

  • Revenue was down 4% on a GAAP basis. Unfavorable movement in FX rates decreased our reported revenue by some $30 million. Further, Q3 '17 included roughly $112 million of revenue from divested assets, particularly iNova and Obagi. So adjusting for both FX and divested assets, our organic growth in Q3 versus 2017 was plus 3%. To put that 3% organic growth rate in context, we overcame a roughly $87 million growth drag in the quarter associated with the LOE assets that are detailed on Slides 27 and 28 in the appendix to our presentation. So a good result.

    以 GAAP 基礎計算,營收下降 4%。匯率(FX)不利變動使我們的報告營收減少約 3,000 萬美元。此外,2017 年第三季包含約 1.12 億美元來自已出售資產的營收,特別是 iNova 與 Obagi。因此,若同時調整匯率與已出售資產因素,我們 2018 年第三季相較 2017 年的有機成長為正 3%。為了讓這 3% 的有機成長率更具脈絡,本季我們克服了約 8,700 萬美元的成長拖累,該拖累與獨占權到期(LOE)資產相關,詳見簡報附錄第 27 與 28 頁投影片。因此這是個不錯的結果。

  • Next, we saw a marked improvement in our reported gross margin compared with the prior year quarter, up some 250 basis points. Three of our 4 segments saw improvement in gross margin, led by Salix, which was up 470 basis points due to a combination of favorable mix and improved gross to nets.

    接下來,我們的報告毛利率相較去年同期顯著改善,上升約 250 個基點。四個部門中有三個部門的毛利率有所提升,其中以 Salix 表現領先,上升 470 個基點,原因是有利的產品組合以及「毛額到淨額」(gross-to-nets)改善的綜合影響。

  • Within the B + L/International segment, our consumer and Rx businesses in Europe and LatAm saw improved gross margins due to favorable mix and better management of inventories resulting in lesser writeoffs.

    在 B + L/International 部門內,我們在歐洲與拉丁美洲的消費者與處方藥(Rx)業務毛利率有所提升,主要受惠於有利的產品組合,以及更佳的庫存管理而使報廢/沖銷減少。

  • International Vision Care was also a meaningful contributor to the gross margin expansion. The better gross margins enabled us to report organic growth at the gross profit line of 6%, double that of our organic revenue growth rate. Selling, advertising and promotional expenses were down or favorable by $20 million, or 4%, 3% on a constant-currency basis.

    International Vision Care 亦是毛利率擴張的重要貢獻者。更佳的毛利率使我們在毛利(gross profit)層面呈現 6% 的有機成長,為有機營收成長率的兩倍。銷售、廣告與促銷費用下降(或優於預期)2,000 萬美元,或 4%;以固定匯率基礎則為 3%。

  • We continued to implement access to improve the efficiency and effectiveness of the dollars we deploy to these activities, with the current focus on our launch products. For example, in Q3 2018 relative to '17, we reduced A&P spending for some assets, and we allocated some of those savings to roughly $17 million of promotional support for LUMIFY, with excellent results.

    我們持續推動各項措施,以提升我們投入於這些活動之資金的效率與效益,目前的重點放在我們的上市產品。例如,2018 年第三季相較於 2017 年,我們降低了部分資產的 A&P 支出,並將其中一部分節省金額重新配置為約 1,700 萬美元的 LUMIFY 促銷支援,成效極佳。

  • G&A expenses were down -- excuse me, were $10 million unfavorable to Q3 of '17. This had more to do with the timing of certain expenses in 2018 than an overall increase in G&A spending. Year-to-date G&A expenses are down some $37 million or 8% favorable to 2017, which more accurately reflects our progress in controlling costs.

    G&A 費用下降——不好意思,是較 2017 年第三季不利 1,000 萬美元。這更多與 2018 年某些費用發生時點有關,而非 G&A 支出整體增加。年初至今的 G&A 費用下降約 3,700 萬美元,較 2017 年有利 8%,這更能準確反映我們在成本控管方面的進展。

  • Our investment in R&D in the quarter totaled $107 million, up $26 million, or 32%, compared to Q3 of 2017. Now we've been talking for some time about our intentions of ramping up our investment in R&D, and I'll make an editorial comment here. The process of increasing our investment in R&D has been a bit slower than we would have liked. That said, we're pleased with where we are in the process, and we'll not sacrifice the productivity of our investments in R&D for speed. We revised our guidance for full year R&D down to approximately $415 million, and we revised our commitment from expecting increase over 2017 to be greater than 15% to being approximately 15%.

    本季我們在研發(R&D)的投資合計 1.07 億美元,較 2017 年第三季增加 2,600 萬美元(或 32%)。我們談論提高研發投資的意圖已一段時間,我在此補充一點評論。提升研發投資的進程比我們期望的稍慢一些。儘管如此,我們對目前的進展感到滿意,而且我們不會為了速度而犧牲研發投資的生產力。我們將全年研發指引下修至約 4.15 億美元,並將原先預期較 2017 年增幅大於 15% 的承諾,修正為約 15%。

  • I have no doubt that the level of our investments in R&D will continue to increase over the next several years and that the level of investments will be sufficient to enable the company to drive organic growth over the long term. The net result for the quarter was that we posted a solid $916 million of adjusted EBITDA, up 5% on an organic basis from Q3 '17.

    我毫不懷疑,未來幾年我們在研發上的投資水準將持續提高,而且投資規模將足以使公司在長期推動內生成長。本季的淨結果是,我們繳出 9.16 億美元的調整後 EBITDA,較 2017 年第三季在有機基礎上成長 5%。

  • While we focus on adjusted EBITDA as our key performance metric, I do want to call out that our adjusted net income for the quarter was up 10% on a reported basis and 17% on a constant-currency basis. The higher growth relative to adjusted EBITDA was due to 2 factors: lower interest expense and a lower adjusted effective tax rate.

    雖然我們以調整後 EBITDA 作為關鍵績效指標,但我也想特別指出,本季調整後淨利在報告基礎上成長 10%,在固定匯率基礎上成長 17%。相較於調整後 EBITDA 較高的成長,主要來自兩項因素:利息費用較低,以及調整後有效稅率較低。

  • Our average debt balance in Q3 of '18 was some $2.4 billion less than in Q3 of '17, and that, combined with lower noncash interest expense, reduced our total interest expense versus Q3 of '17 by some $39 million. Our effective tax rate on adjusted pretax earnings in Q3 of '18 was considerably less than in Q3 of '17. Now I wouldn't read too much into the tax rate in any 1 quarter in isolation, as small changes in our estimates of pretax income by jurisdiction for the full year can produce large swings in our quarterly effective tax rate.

    2018 年第三季我們的平均債務餘額較 2017 年第三季少約 24 億美元,加上較低的非現金利息費用,使我們相較 2017 年第三季的總利息費用減少約 3,900 萬美元。2018 年第三季我們在調整後稅前盈餘上的有效稅率,明顯低於 2017 年第三季。不過,我不會過度解讀任何單一季度的稅率,因為我們對全年各司法管轄區稅前所得的估計只要有小幅變動,就可能導致季度有效稅率出現大幅波動。

  • In Q3 of '18, our ETR on adjusted pretax was circa 7%. Year-to-date, the rate is roughly 10%, and we're guiding to a rate of roughly 11% for the full year.

    2018 年第三季,我們調整後稅前的 ETR 約為 7%。年初至今約為 10%,而我們對全年指引約為 11%。

  • I want to turn quickly to each of the 4 segments to provide a little color, starting with the B + L/International segment on Slide 8.

    我想快速轉到四個事業部門,提供一些補充說明,先從投影片 8 的 B + L/International 部門開始。

  • Revenue was up 3% on an organic basis, the 8th consecutive quarter of organic growth. Importantly, the growth for the segment was driven by a 4% increase in volumes and offset by a roughly 100 basis point decline in realized net prices. Four of the 5 subsegments posted organic growth, and all 5 saw increased volume over the prior year quarter. The growth in Global Vision Care was led by the U.S., which grew 8% organically. Growth outside the U.S. was strongest in Japan. Global Surgical was up 3% organically and was consistent as between the U.S. and OUS businesses.

    營收在有機基礎上成長 3%,為連續第 8 個季度的有機成長。重要的是,該部門的成長由銷量增加 4% 所帶動,但被已實現淨價格約下降 100 個基點所抵銷。五個子部門中有四個呈現有機成長,且五個子部門的銷量皆較去年同期增加。全球視力保健(Global Vision Care)的成長由美國帶動,美國有機成長 8%。美國以外的成長以日本最強。全球手術(Global Surgical)有機成長 3%,美國與美國以外(OUS)業務表現一致。

  • Global Consumer was up 3% organically, also led by the U.S., where we posted strong gains with our eye vitamins, Ocuvite and PreserVision, and from the ramp of LUMIFY.

    全球消費者(Global Consumer)有機成長 3%,同樣由美國帶動;我們的眼部維他命產品 Ocuvite 與 PreserVision 表現強勁,且 LUMIFY 放量推進亦帶來貢獻。

  • Global Ophtho Rx was up 9% organically, aided by revenue from Vyzulta in the U.S. and strong regional performances from our Turkey, Greece, Middle East, Africa cluster, the U.K. and Eastern Europe.

    全球眼科處方藥(Global Ophtho Rx)有機成長 9%,受惠於 Vyzulta 在美國的營收,以及土耳其、希臘、中東、非洲集群、英國與東歐等地區的強勁表現。

  • The International Pharma business was flat organically over the year-ago quarter, with solid growth in our Egyptian business Amoun and our Latin American business. Growth in those regions was offset by softness in Eastern Europe and Russia.

    國際製藥(International Pharma)業務相較去年同期在有機基礎上持平;其中埃及業務 Amoun 與拉丁美洲業務有穩健成長。上述地區的成長被東歐與俄羅斯的疲弱所抵銷。

  • Moving to the Salix segment on Slide 9. Salix revenue grew $8 million, or 2%, despite the impact of LOEs that totaled some $31 million. That's mainly UCERIS tablets. XIFAXAN grew 11%, mainly from improved realized net pricing. TRxs for XIFAXAN, a proxy for units, were up 9% compared with Q3 of '17. RELISTOR grew 88% on improved realized net pricing and a strong increase in volume.

    接著看投影片 9 的 Salix 部門。儘管專利到期(LOEs)影響合計約 3,100 萬美元,Salix 營收仍增加 800 萬美元(或 2%)。主要是 UCERIS 錠劑。XIFAXAN 成長 11%,主要來自已實現淨價格改善。XIFAXAN 的處方量(TRxs,作為單位數的替代指標)較 2017 年第三季增加 9%。RELISTOR 在已實現淨價格改善及銷量大幅增加的帶動下成長 88%。

  • A quick note on the improvements we are seeing in the net realized pricing of a number of our branded pharma products. In 2017, we kicked off initiatives to improve the gross to nets on our branded pharma products, focusing on things including the cost and effectiveness of copay assistance cards, the level of our discounting to nonretail accounts and the magnitude of product returns. You've started to see some of the benefits of these activities in Q1 of this year, for example, the improvement you saw in XIFAXAN realized net pricing based on changes to our nonretail discounting practices.

    簡要說明一下我們在多項品牌製藥產品的已實現淨價格所看到的改善。2017 年,我們啟動改善品牌製藥產品「毛額到淨額」(gross to net)的計畫,重點包括共付額協助卡(copay assistance cards)的成本與效益、對非零售客戶的折扣水準,以及產品退貨的幅度。你們已在今年第一季開始看到部分效益,例如,因我們調整非零售折扣作法而帶來的 XIFAXAN 已實現淨價格改善。

  • I'm going to segue to a quick tutorial -- accounting tutorial about the gross to net items. If actual levels of gross to net deductions for a product decline during a quarter, there's an obvious improvement in realized net pricing. And you can expect that the improvement will continue until there's a change in the programs driving the reduced level of process gross to net deductions. Less obvious is the ephemeral benefit of rebasing the accruals for the gross to net items. With lesser observed deductions, the period-ending accrual needs to be reduced with the result being a further improvement in the realized net pricing in the period, which is on top of the already noted improvement driven by the reduced level of process deductions. This so-called true-up of gross to net accruals can drive significant variances in shorter periods of time, like a quarter, but normalize over longer periods of time.

    我接著做一個簡短教學——會計教學,說明毛額到淨額項目。若某產品在一個季度內實際的毛額到淨額扣減(gross to net deductions)水準下降,已實現淨價格就會有明顯改善。而你可以預期,這項改善會持續,直到驅動扣減水準降低的方案發生變化為止。較不明顯的是,重新基準化毛額到淨額項目應計數(accruals)所帶來的短暫效益。當觀察到的扣減變少,期末應計數就需要下調,結果是在該期間的已實現淨價格進一步改善,且是在前述因流程扣減水準降低所帶來的改善之外的額外提升。這種對毛額到淨額應計數的所謂「調整」(true-up),可能在較短期間(如單一季度)造成顯著差異,但在較長期間會趨於正常化。

  • In our Q3 2018 results versus Q3 of '17, you see this phenomenon with RELISTOR, and you're going to see it again when I talk about dermatology and our neurology businesses.

    在我們 2018 年第三季相較 2017 年第三季的結果中,你會在 RELISTOR 看到這種現象;而當我談到皮膚科與神經科業務時,你也會再次看到。

  • On to the Ortho Dermatologics segment on Slide 10. I want to call your attention to the medical derm part of this segment that was down 1% organically. Volumes in our medical derm business were off substantially versus Q3 of '17, but were nearly offset by improved realized net pricing driven by our efforts to more effectively manage gross to nets in this segment. That's the initiatives I just spoke of in my review of Salix.

    接著看投影片 10 的 Ortho Dermatologics 部門。我想請各位注意該部門中的醫學皮膚科(medical derm)部分,其有機下滑 1%。我們醫學皮膚科業務的銷量相較 2017 年第三季大幅下降,但幾乎被已實現淨價格改善所抵銷;該改善來自我們在此部門更有效管理毛額到淨額的努力。這就是我在回顧 Salix 時提到的那些措施。

  • We have not taken price increases in our medical derm portfolio, so almost the entirety of the improvement in net pricing came from reduced rebates on copay assistance cards, lesser actual levels of product returns and the beneficial impact of truing up the associated gross to net accruals that had the effect of magnifying the improvement in gross to nets when looking at the quarter in isolation. Of those 3, the true-up of the accruals was the most significant factor, important. Revenue in the medical derm part of this segment in Q4 will revert to something closer to what we saw in the first 2 quarters of this year, as the magnitude of the favorable true-up of accruals seen in Q3 will not repeat in the future.

    我們在醫學皮膚科產品組合並未進行漲價,因此淨定價改善幾乎全部來自於降低共付額協助卡的回扣、實際產品退貨水準下降,以及對相關毛額轉淨額(gross-to-net)應計項目的調整(true-up)所帶來的有利影響;在單獨觀察本季時,這些調整具有放大毛轉淨改善幅度的效果。在這三項因素中,應計項目的調整是最重要、最顯著的因素。本分部中醫學皮膚科在第四季的營收將回到更接近今年前兩季的水準,因為第三季所見到的有利應計調整幅度未來不會再重複出現。

  • Solta continued to perform very well under leadership of Tom Hart. Revenue was up 15% on an organic basis, with a strong growth in equipment sales in the U.S. That's VASER, Fraxel and Clear + Brilliant and growth in the Asia Pacific region driven by the launch of Thermage FLX. The growth in Solta was volume-driven as realized net pricing declined versus Q3 of '17.

    在 Tom Hart 的領導下,Solta 持續表現非常出色。以有機基礎計算,營收成長 15%,其中美國設備銷售強勁成長,包括 VASER、Fraxel 與 Clear + Brilliant;亞太地區的成長則由 Thermage FLX 的上市所帶動。Solta 的成長主要由銷量驅動,因為實現的淨定價相較於 2017 年第三季有所下降。

  • On to diversified on Slide 11. Overall, the segment was up 4% on an organic basis. The neuro business was down $16 million or 7% organically. The impact of the LOE assets compared with Q3 of '17 was minus $54 million, but that decline was offset in part by growth in the sales of several promoted products within this portfolio, mainly Wellbutrin and Aplenzin, which together grew 15% compared with Q3 of '17 and also the favorable impact of the gross to net initiatives I talked about in covering both Salix and Ortho Derm. The U.S. generics business was the star of this segment, up $35 million, or plus 43%, compared with Q3 of '17. Roughly half of this growth came from launches of authorized generic versions of our products that lost exclusivity and the other half from our ability to capitalize on market opportunities within our broader generic portfolio. I've said this in the past, but the leader of our diversified segment, Barbara Purcell, and her entire team do a great job of maximizing the value of the assets in this segment. Our dentistry business is facing reimbursement challenges, and we saw a revenue decline in that business compared with the prior year quarter.

    接著看第 11 張投影片的多元化業務。整體而言,本分部以有機基礎計算成長 4%。神經科業務有機下滑 1,600 萬美元,或 7%。與 2017 年第三季相比,專利到期(LOE)資產的影響為減少 5,400 萬美元,但該降幅部分被此產品組合中數個重點推廣產品的銷售成長所抵銷,主要是 Wellbutrin 與 Aplenzin,兩者合計較 2017 年第三季成長 15%,以及我在說明 Salix 與 Ortho Derm 時提到的毛額轉淨額(gross-to-net)措施所帶來的有利影響。美國學名藥業務是本分部的亮點,較 2017 年第三季增加 3,500 萬美元,或成長 43%。約一半的成長來自於我們對已失去獨家權產品推出授權學名藥版本,另一半則來自於我們把握更廣泛學名藥產品組合中的市場機會的能力。我過去也說過,多元化分部負責人 Barbara Purcell 及其整個團隊在最大化本分部資產價值方面做得非常出色。我們的牙科業務正面臨給付(reimbursement)方面的挑戰,因此該業務營收較去年同期季度下滑。

  • Switching gears and moving to the balance sheet on Slide 12. Here, you see the progression of our total debt. We were just above $25 billion at quarter close, and we ended with $973 million of cash.

    接著轉換主題,來看第 12 張投影片的資產負債表。在這裡你可以看到我們總負債的變化趨勢。季度結束時我們略高於 250 億美元,期末現金為 9.73 億美元。

  • On to the cash flow summary on Slide 13. It was a strong cash flow quarter for us, as we generated $522 million of cash from operations. We used that cash flow to repay more than $360 million of debt during the quarter, and just 2 weeks ago, we repaid another $125 million of debt to bring our debt under $25 billion today. The $1.182 billion of cash from operations generated year-to-date represents an average of $394 million per quarter, but that average was depressed by a number of nonrecurring cash payments we've made so far in 2018, such as the Solodyn settlement, which was paid out in '18 and the Allergan settlement. We continue to believe that our business has the capacity to generate cash flow operations in the low $400 million range per quarter on average.

    接著看第 13 張投影片的現金流摘要。本季對我們而言是強勁的現金流季度,我們自營運產生 5.22 億美元現金。我們用這些現金流在本季償還超過 3.60 億美元的債務,而就在兩週前,我們又償還了 1.25 億美元債務,使得目前債務降至 250 億美元以下。年初至今自營運產生的 11.82 億美元現金,平均每季為 3.94 億美元,但該平均值受到我們在 2018 年迄今所支付的若干一次性(非經常性)現金款項所壓低,例如 Solodyn 和解金(於 2018 年支付)以及 Allergan 和解金。我們仍然相信,我們的業務具備平均每季在 4 億美元出頭(low $400 million range)的營運現金流產生能力。

  • Next, our revised guidance on Slide 14. On the face of it, we're holding our revenue guidance in the range of $8.15 billion to $8.35 billion. However, that's far from the entire story. FX rates from August until now decreased our full year outlook by $15 million. Our revised view of the trajectory, the LOE assets improved by some $70 million, and we increased our forecast for the balance of our business by some $45 million. So net-net, that would have been plus $100 million at the revenue line compared with our prior guidance. However, as part of our CORE program, and I would remind you if you don't remember, CORE stands for cost optimization and revenue enhancement, we are implementing a change to our distribution strategy for our U.S.-branded pharmaceutical products. This change is expected to generate some $15 million to $20 million of improvement in our gross to net per year from here forward. In addition, this change will enable us to improve our supply chain logistics, thereby improving efficiency and will help us reduce our investment in working capital. All good things, good things that come at the onetime cost of absorbing a reduction in wholesale pipeline inventories during Q4 of this year. The impact of this initiative relative to us continuing as we have in the past is that Q4 2018 and full year 2018 net sales will be reduced by some $100 million. Since we disclose our wholesale pipelines to you each quarter, you'll be able to see the expected reductions in pipeline inventories when we report our full year 2018 and Q4 results. To be clear, this reduction in our revenue forecast for '18 is the result of a tactical decision on our part. The long-term returns that we will realize by forgoing near-term revenue and the associated profits are unassailable.

    接下來是第 14 張投影片的更新後指引。表面上看,我們維持營收指引在 81.5 億至 83.5 億美元區間。然而,這遠非全部故事。自 8 月至今的匯率(FX)變動使我們全年展望減少 1,500 萬美元。我們對趨勢的修正使專利到期(LOE)資產的表現改善約 7,000 萬美元,並將其餘業務的預測上調約 4,500 萬美元。因此,若以淨額計算,相較於先前指引,營收端本應增加約 1 億美元。然而,作為我們 CORE 計畫的一部分——若你不記得,我提醒一下,CORE 代表成本優化與營收提升(cost optimization and revenue enhancement)——我們正在對美國品牌處方藥產品的通路策略進行調整。預期此變更自今往後每年可帶來約 1,500 萬至 2,000 萬美元的毛額轉淨額(gross-to-net)改善。此外,此變更將使我們能改善供應鏈物流,進而提升效率,並有助於降低我們在營運資金上的投入。這些都是好事,但其代價是在今年第四季一次性吸收批發通路管線庫存(wholesale pipeline inventories)下降所帶來的影響。相較於我們過去延續既有作法,該措施對 2018 年第四季及 2018 全年淨銷售額的影響將是減少約 1 億美元。由於我們每季都會向各位揭露批發通路管線水位,因此當我們公布 2018 全年與第四季結果時,你們將能看到預期的管線庫存下降。需要說清楚的是,我們對 2018 年營收預測的下調是源於我們所做的一項戰術性決策。我們透過放棄短期營收及其相關利潤而在長期所能實現的回報是無可置疑的。

  • We're increasing the range for our full year 2018 adjusted EBITDA guidance by $100 million across the range, as you'll see on the bridge on Slide 15. It's the combination of, one, the changes in FX rates; second, the increased profit from higher forecast revenues for the LOE asset; and third, the improved forecast for our base business. All those 3 things together would have allowed us to raise our adjusted EBITDA range by some $185 million. However, the decision to change our distribution strategy for our branded pharma products reduces our adjusted EBITDA expectations for 2008 and limits the raise to $100 million. Still wicked good.

    如第 15 張投影片的橋接圖所示,我們將 2018 全年調整後 EBITDA 指引區間整體上調 1 億美元。這是以下因素的組合:第一,匯率(FX)變動;第二,專利到期(LOE)資產因較高的營收預測而帶來的利潤增加;第三,我們基礎業務預測的改善。這三項合計原本可讓我們將調整後 EBITDA 區間上調約 1.85 億美元。然而,調整品牌處方藥產品通路策略的決策降低了我們對 2008 年調整後 EBITDA 的預期,並將上調幅度限制在 1 億美元。仍然非常好。

  • You will note that we are maintaining relatively broad guidance ranges for both revenue and adjusted EBITDA. While we stand by our estimates of the impact of the change to the U.S. pharma distribution strategy, where we actually land with respect to that initiative could vary from our expectations.

    你會注意到,我們對營收與調整後 EBITDA 仍維持相對較寬的指引區間。雖然我們支持對美國藥品通路策略變更影響的估計,但該措施最終實際落點仍可能與我們的預期有所差異。

  • In summary, for me, we had a strong quarter and feel really good about the balance of 2018. Since Joe got here in early 2016, we made real strides in improving our operations, investing behind growth, generating cash and using that cash to address our leverage. The cumulative impact of those efforts plus the steps we're taking in Q4 this year will enable us to enter 2019 in really good shape. Back to you, Joe.

    總結來說,我們本季表現強勁,並對 2018 年剩餘期間感到非常有信心。自 Joe 在 2016 年初加入以來,我們在改善營運、加大成長投資、產生現金並運用現金處理槓桿水準方面取得了實質進展。這些努力的累積效果,加上我們在今年第四季採取的步驟,將使我們能以非常良好的狀態進入 2019 年。交回給你,Joe。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Thank you, Paul. Let's go through some of the highlights in our Bausch + Lomb/International segment on Slide #16. First, this segment delivered its 8th consecutive quarter of organic growth, as you can see in the graph on the left. Importantly, this growth was driven by increased volume across all 5 reporting businesses of the segment. In the aggregate, the top 10 products in this segment grew organically by 7% compared to the prior year quarter.

    謝謝你,Paul。讓我們看一下第 16 張投影片中 Bausch + Lomb/國際分部的一些重點。首先,如左側圖表所示,本分部已連續第 8 個季度實現有機成長。重要的是,這項成長是由本分部所有 5 個申報業務的銷量增加所驅動。整體而言,本分部前 10 大產品的有機成長率較去年同期季度為 7%。

  • The Global Consumer business delivered another quarter of great performance. LUMIFY, which was launched in May, is already the #1 physician-recommended product in the Redness Reliever category. LUMIFY is also one of the top 2 brands in the category, achieving a weekly market share of 26% as measured by dollar -- retail dollar sales.

    全球消費者業務在本季再度交出亮眼表現。於5月上市的LUMIFY,已成為「消除眼紅」類別中醫師最推薦的第1名產品。LUMIFY亦為該類別前2大品牌之一,按零售美元銷售額衡量,其每週市占率達26%。

  • The e-commerce trend remains positive for our consumer product. Amazon continues to be a strong channel, with sales up 41% in the third quarter compared to the prior year quarter. And finally, for the consumer business, the Bausch + Lomb eye vitamins PreserVision and Ocuvite together are the #1 brand and the #1 driver of growth in eye vitamins category. These products grew organically by 11% in the third quarter 2018 versus last year on a combined basis.

    我們消費性產品的電商趨勢仍維持正向。Amazon持續是強勁通路,第三季銷售額較去年同期成長41%。最後,就消費者業務而言,Bausch + Lomb 眼部維他命PreserVision與Ocuvite合計為眼部維他命類別的第1大品牌,也是成長的第1大推動力。這些產品在2018年第三季合計口徑下,較去年同期有機成長11%。

  • Moving on to the Vision Care on Slide 17. When it comes to contact lenses, one of our teams mantras is comfort, vision, health. And this clear focus is resonating with consumers. Vision Care's strong performance in the third quarter was driven by continued market share gains outpacing the competitors. Internationally, growth was driven by Asia, Russia and Latin America.

    接著看第17頁的視力保健(Vision Care)。談到隱形眼鏡,我們團隊的一句口號是:舒適、視覺、健康。而這個清晰的聚焦正引起消費者共鳴。視力保健第三季的強勁表現,主要由持續的市占提升所帶動,且增速超越競爭對手。在國際市場方面,成長主要由亞洲、俄羅斯與拉丁美洲帶動。

  • The chart on the left illustrates the performance of our U.S. Vision Care business since we installed new management at the end of the first quarter of 2017. You can see the impact of this change beginning with the third quarter of 2017, up 9%. We're up 15% in the fourth quarter, 15% in the first quarter and so on. This is an example of an effective Vision Care team that is delivering great results.

    左側圖表說明自2017年第一季末我們導入新管理團隊以來,美國視力保健業務的表現。你可以看到這項變革的影響自2017年第三季開始顯現,成長9%。第四季成長15%,第一季成長15%,以此類推。這是視力保健團隊有效運作並交出優異成果的例證。

  • Turning now to Vyzulta. On the bottom right, we've included the weekly script data for Vyzulta since the beginning of the year, which shows a growth of 20% from the second to the third quarter of 2018. In terms of market access, our position is substantially improved. Our continued coverages now include Express Scripts commercial; a CVS commercial, which started in mid-October; and the AARP Part D, which started on October 1. We have efforts underway on several other plans and expect improved overall access in the fourth quarter.

    接著談Vyzulta。右下角我們列出Vyzulta自年初以來的每週處方數據,顯示2018年第二季到第三季成長20%。就市場准入而言,我們的地位已大幅改善。我們目前持續的給付涵蓋包括:Express Scripts商業保險;CVS商業保險(於10月中旬開始);以及AARP Part D(於10月1日開始)。我們也正推進其他多個方案,並預期第四季整體准入將進一步改善。

  • On Slide 18, Salix revenue growth of 2% was driven by continued strong fundamental execution across XIFAXAN and RELISTOR despite the loss of exclusivity for UCERIS. XIFAXAN revenue increased by 11% compared to the third quarter of 2017. The RELISTOR franchise revenue increased by 88% compared to the third quarter of 2017.

    在第18頁,Salix營收成長2%,主要由XIFAXAN與RELISTOR持續強勁的基本面執行所帶動,儘管UCERIS已喪失獨家權。XIFAXAN營收較2017年第三季成長11%。RELISTOR產品線營收較2017年第三季成長88%。

  • Also, we have now resolved the significant Salix legal legacy matters, and as a result, we have reduced uncertainty around this business. A few more highlights for XIFAXAN. TRx unit volume grew by 9% versus the prior year quarter, and we are seeing continued accelerated growth quarter-over-quarter.

    此外,我們現已解決Salix重要的歷史法律事項,因此降低了該業務的不確定性。再補充幾點XIFAXAN的重點。TRx處方量較去年同期成長9%,且我們看到季度對季度的加速成長持續。

  • As you can see from the chart on the right, NRx share continues in primary care, up 21 share points since February 2017 as a result of strong execution in the field.

    如右側圖表所示,NRx在基層醫療(primary care)的市占持續提升;自2017年2月以來,因前線強力執行而上升21個市占點。

  • Let's move over to Slide 19 and talk about Salix product portfolio. We have a number of programs in the works for rifaximin. First, we're continuing to enroll patients in a study that we initiated earlier this year with a new formulation of rifaximin for acute overt hepatic encephalopathy. Activities are underway for a small intestinal bacterial overgrowth, or SIBO, study, which is expected to commence in the first half of 2019. Resolving the arbitration with Alfasigma has resulted in 2 important benefits for Salix: one, we have confirmed the rights we have under our existing license agreement to the extended intestinal release formulation of rifaximin; and two, we expect to initiate a late-stage clinical program to study an investigational formulation of rifaximin in patients with postoperative Crohn's disease, which is an area of unmet need.

    我們看第19頁,談Salix的產品組合。我們正在推進多項與rifaximin相關的計畫。首先,我們持續招募病患參與一項研究;該研究於今年稍早啟動,使用rifaximin的新劑型,用於急性顯性肝性腦病變。針對小腸細菌過度生長(SIBO)的研究也在進行相關準備,預計於2019年上半年開始。與Alfasigma的仲裁案解決,為Salix帶來兩項重要效益:第一,我們確認在既有授權協議下,對rifaximin延長腸道釋放劑型所擁有的權利;第二,我們預期將啟動一項後期臨床計畫,研究一種rifaximin的試驗性劑型,用於術後克隆氏症患者;此領域仍有未被滿足的醫療需求。

  • According to the Crohn's & Colitis Foundation, more than 750,000 Americans have Crohn's disease, and of those, up to 75% will eventually require surgery.

    根據克隆氏症與結腸炎基金會(Crohn's & Colitis Foundation),超過75萬名美國人罹患克隆氏症,其中多達75%最終將需要手術。

  • There are 2 additional partnership opportunities that I want to mention. First, we've expanded our microbiome research and discovery through a strategic collaboration with Cedars-Sinai Medical Center, and as we mentioned in the last quarter's call, we have also agreed to expand the license term for 3 additional budesonide programs from Dr. Falk Pharma.

    另外還有兩個合作機會我想提及。第一,我們透過與Cedars-Sinai醫學中心的策略合作,擴大了腸道微生物群(microbiome)的研究與探索;此外,如同我們在上一季電話會議中提到的,我們也同意將Dr. Falk Pharma的另外3項budesonide計畫之授權期限延長。

  • I also want to review a few new products in the Salix that have recently launched or are now launching. LUCEMYRA launched in August as part of a copromotional arrangement with US WorldMeds is the first and only nonopioid medication for the mitigation of withdrawal symptoms after abrupt discontinuation of opioids in adults.

    我也想回顧幾項Salix近期已上市或正在上市的新產品。LUCEMYRA於8月上市,作為與US WorldMeds共同推廣安排的一部分;它是首個且唯一的非鴉片類藥物,用於成人在突然停止使用鴉片類藥物後,緩解戒斷症狀。

  • LUCEMYRA is a perfect bolt-on to our ongoing RELISTOR promotions. PLENVU is a one leader PEG bowel-cleansing preparation for colonoscopies launched in the United States in September. The third product that I want to highlight is DOPTELET, which was approved by the FDA in May of 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Under our exclusion copromotion arrangement with Dova Pharmaceuticals, about 100 sales reps will begin promoting DOPTELET to gastroenterology health care professionals in mid-October, another synergistic bolt-on promotion opportunity for our gastroenterology team.

    LUCEMYRA是我們持續推廣RELISTOR的理想加掛產品。PLENVU是一種1公升PEG腸道清潔製劑,用於大腸鏡檢查,已於9月在美國上市。我想強調的第三項產品是DOPTELET,於2018年5月獲FDA核准,用於治療慢性肝病且預計接受處置/手術之成人患者的血小板減少症。依據我們與Dova Pharmaceuticals的排他性共同推廣安排,約100名業務代表將於10月中旬開始向胃腸科醫療專業人員推廣DOPTELET,這也是我們胃腸科團隊另一個具協同效益的加掛推廣機會。

  • Moving on to Slide 20 for Ortho Dermatologics. Total segment organic revenue growth was modest in the quarter, up 1% as the business continues to stabilize. Global Solta had another strong quarter, particularly in key markets of U.S., China, South Korea and Japan. Revenues grew organically by 15% versus the third quarter of 2017, driven by demand and the expected global launch of Thermage FLX, a noninvasive skin-tightening treatment.

    接著看第20頁的Ortho Dermatologics。本季該事業群的有機營收成長幅度不大,年增1%,業務持續趨於穩定。Global Solta本季再度表現強勁,尤其在美國、中國、南韓與日本等關鍵市場。營收較2017年第三季有機成長15%,主要由需求帶動,以及Thermage FLX(非侵入式緊膚治療)預期的全球上市所推動。

  • When I think about the future of the dermatology business, I think about 3 things: new products, new products and new products. Our ability to develop and commercialize these new products will determine our success. And the good news is that our recent new products are doing well.

    談到皮膚科業務的未來,我想到三件事:新產品、新產品,還是新產品。我們開發並商業化這些新產品的能力,將決定我們的成功。好消息是,我們近期的新產品表現良好。

  • First, SILIQ. As you can see from the chart on the right, TRx weekly scripts saw more than a 65% TRx growth in the third quarter versus the prior quarter due to continued marketing initiatives and increasing REMS certifications. To date, we have REMS certified over 3,900 prescribers for SILIQ.

    首先是SILIQ。如右側圖表所示,由於持續的行銷措施以及REMS認證數增加,第三季TRx每週處方數較前一季成長超過65%。截至目前,我們已為SILIQ完成REMS認證的開立醫師超過3,900位。

  • TRx weekly scripts of Retin-A Micro 0.06% and 0.08% on a combined basis saw a more than 50% TRx growth versus last year.

    Retin-A Micro 0.06%與0.08%合計的TRx每週處方數,較去年成長超過50%。

  • At the end of October, we launched ALTRENO, an innovative new acne treatment. ALTRENO provides the trusted efficacy of tretinoin but in a lotion formulation that is generally well tolerated and helps hydrate and moisturize the skin. In addition, we're investing in a number of potential treatments for acne and atopic dermatitis that are progressing nicely through our pipeline, which you can see on the bottom right of Slide 20. Phase III studies for IDP-120 are expected to begin later this month, and we are expecting to submit an NDA for IDP-123 in the first half of 2019.

    在10月底,我們推出了 ALTRENO,一款創新的全新痤瘡治療產品。ALTRENO 提供維A酸(tretinoin)值得信賴的療效,但採用一般耐受性良好、並有助於為皮膚補水與保濕的乳液劑型。此外,我們也正投資多項潛在的痤瘡與異位性皮膚炎治療方案,這些項目在我們的研發管線中進展順利,您可在投影片20右下角看到。IDP-120 的第三期研究預計將於本月稍晚開始,而我們預期將於2019年上半年提交 IDP-123 的 NDA(新藥申請)。

  • On to Slide 21. Let me now take a moment to address BRYHALI and DUOBRII, 2 novel psoriasis treatments. Psoriasis presents a large and growing market opportunity. Approximately 7.5 million people in the United States are living with psoriasis, and there are 150,000 to 250,000 new cases each year. It's important to remember that the clinical picture of psoriasis is not uniform. The condition exists on a spectrum of severity ranging from mild and occasional to severe and chronic. Treatment options are not uniform either, ranging from topical steroid creams to intervenous biologics.

    接著看投影片21。我現在花點時間談談 BRYHALI 與 DUOBRII 這兩款新型乾癬治療產品。乾癬帶來龐大且持續成長的市場機會。美國約有750萬人罹患乾癬,每年新增病例約15萬至25萬例。重要的是要記住,乾癬的臨床表現並不一致。其嚴重程度呈現光譜分布,從輕微且偶發到嚴重且慢性皆有。治療選項也不一致,從外用類固醇乳膏到靜脈注射的生物製劑不等。

  • On the left, we show you where we believe BRYHALI and DUOBRII would fall on the spectrum of severity. Our market research has shown that while there is some overlap, health care providers will use BRYHALI differently than DUOBRII with different patient populations. BRYHALI is expected to be a new potent steroid treatment for plaque psoriasis and novel vehicle lotion. Safety has been established in clinical trials with dosing for up to 8 weeks, with no increase in epidermal atrophy. It's an appropriate treatment for patients with mild-to-moderate symptoms.

    在左側,我們向各位展示我們認為 BRYHALI 與 DUOBRII 在嚴重程度光譜中所處的位置。我們的市場研究顯示,雖然兩者有部分重疊,但醫療照護提供者會以不同方式使用 BRYHALI 與 DUOBRII,並針對不同的病患族群。BRYHALI 預期將成為治療斑塊型乾癬的新型強效類固醇療法,並採用新型載體乳液。臨床試驗已在最高8週的給藥期間建立其安全性,且未見表皮萎縮增加。它適用於症狀輕度至中度的病患。

  • DUOBRII is expected to be the first and only topical lotion that contains a unique combination halobetasol and tazarotene in one formulation, which allows for a potentially expanded duration of use. If approved, DUOBRII would be an appropriate treatment for patients who present with more moderate-to-severe symptoms, including chronic or long-lasting episodes and thicker, stubborn plaques. Due to the unique formulations that allows for a longer duration of use, DUOBRII has the potential to reduce the cost of treatment by up to 75% versus injectable biologics. That's important for patients, physicians and payers.

    DUOBRII 預期將成為首款且唯一一款在同一配方中含有獨特組合 halobetasol 與 tazarotene 的外用乳液,從而可能延長可使用的療程期間。若獲核准,DUOBRII 將適用於症狀較中度至重度的病患,包括慢性或持續時間較長的發作,以及較厚、頑固的斑塊。由於其獨特配方可延長使用期間,DUOBRII 相較於注射型生物製劑,具有將治療成本最多降低75%的潛力。這對病患、醫師與支付方都很重要。

  • On Slide 22, we show the current state of the Significant Seven products, which represent our core growth drivers over the next 5 years. As an update from the last quarter's call, SiHy Daily lenses were launched in Japan in September. BRYHALI is expected to launch later this month. And as a reminder, DUOBRII has a PDUFA date coming up in February 2019.

    在投影片22,我們展示「重要七大」(Significant Seven)產品的現況,這些產品將是我們未來5年的核心成長驅動力。作為上季電話會議以來的更新,SiHy Daily 鏡片已於9月在日本上市。BRYHALI 預計將於本月稍晚上市。並提醒各位,DUOBRII 的 PDUFA 日期將於2019年2月到來。

  • On Slide 23, we show our late-phase pipeline and recent launches. As you can see, each of these 3 segments is working to develop a best-in-class and diversified pipeline of new ophthalmology, dermatology and GI products that we believe will expand our portfolio and fuel future growth. Now we have a new ophthalmology gel for ocular inflammation, with a PDUFA date coming up in February. We're excited about the rifaximin programs I highlighted earlier, and our late-stage derm pipeline has a lot of potential. On an annualized basis, the products we've launched since 2016 are growing and generating approximately $300 million of revenue.

    在投影片23,我們展示後期研發管線與近期上市產品。如各位所見,這三個領域各自致力於打造同級最佳且多元化的新眼科、皮膚科與腸胃(GI)產品研發管線;我們相信這將擴充我們的產品組合並推動未來成長。目前我們有一款用於眼部發炎的新眼科凝膠,其 PDUFA 日期將於2月到來。我們對先前提到的 rifaximin 計畫感到振奮,而我們後期皮膚科研發管線也具備很大潛力。以年化基礎計算,自2016年以來我們推出的產品正在成長,並帶來約3億美元的營收。

  • Finally, Slide #24 reviews the 2018 commitments and expected targets we outlined at the beginning of the year. Having now delivered 3 consecutive quarters of overall organic revenue growth, we are very pleased with our progress. To summarize, all 4 of our segments grew organically for the first time in the third quarter. Our top 10 products in aggregate grew organically by 7% in the quarter. We generated $522 million of cash from operations. We improved working capital by more than 25% since the second quarter of 2016. We reduced our total debt to under $25 billion. We raised our full year adjusted EBITDA guidance range for the third time this year. We resolved approximately 60 legal matters, including 3 important legacy issues for the Salix business. We resolved the XIFAXAN IP litigation and expect to preserve market exclusivity for our top product until 2028.

    最後,投影片#24 回顧我們在年初提出的2018年承諾與預期目標。在已連續3個季度實現整體有機營收成長之後,我們對進展感到非常滿意。總結而言,我們四個事業部在第三季首次全部實現有機成長。我們前十大產品合計在本季有機成長7%。我們自營運活動產生5.22億美元現金。自2016年第二季以來,我們將營運資金改善超過25%。我們將總負債降至250億美元以下。我們今年第三次上調全年調整後 EBITDA 指引區間。我們解決了約60件法律事項,其中包括 Salix 業務的3項重要歷史遺留議題。我們解決了 XIFAXAN 的智慧財產權訴訟,並預期可將我們最重要產品的市場獨占性維持至2028年。

  • And finally, we have made responsible pricing decisions, are committed to continue to do so because approximately 51% of our revenues come from a diversified mix of medical devices, OTC products and prescription branded and generic products that are not exposed to the U.S. branded prescription drug pricing environment.

    最後,我們已做出負責任的定價決策,並承諾將持續如此,因為約51%的營收來自多元組合的醫療器材、OTC 產品,以及處方品牌藥與學名藥,這些產品不受美國品牌處方藥定價環境的影響。

  • Overall, great progress towards achieving operational excellence.

    整體而言,我們在達成卓越營運方面取得了很大進展。

  • With that, operator, let's open up the line for questions. Operator?

    接下來,接線員,請開放電話線讓大家提問。接線員?

  • Operator

    Operator

  • (Operator Instructions) The first question will be from David Risinger with Morgan Stanley.

    (接線員指示) 第一個問題來自摩根士丹利(Morgan Stanley)的 David Risinger。

  • Zhu Shen Ng - Research Associate

    Zhu Shen Ng - Research Associate

  • It's Zhu Shen here for David Risinger. Couple of quick ones. So could you please comment on LUMIFY's global potential, including the opportunity to be bigger than designed? And secondly, what should we assume Lotemax, Cuprimine and APRISO's generic pressures in 2019?

    我是 Zhu Shen,代 David Risinger 提問。有兩個簡短問題。第一,請評論 LUMIFY 的全球潛力,包括其成長機會是否可能超出原先設計的規模?第二,對於2019年 Lotemax、Cuprimine 與 APRISO 的學名藥競爭壓力,我們應如何假設?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Let me start with LUMIFY in terms of the concepts. We think LUMIFY is a very important advance in the treatment of redness relief. The primary reason I say that is LUMIFY works on the venous side of the -- versus on the arterial side where many of the other products work. We -- based on comments from the physicians we've spoken with, that's an important advance in treating redness relief in the eye. That's the reason why we believe it is the #1 recommended product by physicians in this category. Relative to the concept -- we're not going to make any specific comments about the size of the opportunity, although, as I said, we can very quickly point towards the fact that within 4 months now, we're already at the 26% market share. So we're very excited about where it goes -- where that product goes relative to the future opportunities there. But we're really not going to comment on anything specifically at this point about the future product. On the second part of the question on Lotemax, for 2019, one of the comments, I guess, I would say, first and foremost, is that it is not a date-certain launch. So as we look at the slide number -- I'm just...

    我先從 LUMIFY 的概念談起。我們認為 LUMIFY 在緩解眼紅的治療上是一項非常重要的進展。我之所以這麼說,主要原因是 LUMIFY 的作用在靜脈端——相較之下,許多其他產品的作用在動脈端。根據我們與醫師交流所得的回饋,這是在治療眼部泛紅方面的一項重要進展。這也是我們相信它在此類別中是醫師最推薦的第1名產品的原因。至於機會規模——我們不會對機會大小做任何具體評論;不過,如我所說,我們可以很快指出一點:上市至今4個月,我們已達到26%的市占率。因此,我們對該產品未來的走向——以及相對於未來機會的發展——感到非常振奮。但此時此刻,我們確實不會就未來產品做任何具體評論。至於問題的第二部分、關於 Lotemax 在2019年的情況,我想首先要說的是,它並不是一個確定日期的上市事件。因此當我們看投影片編號——我只是……

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • 27.

    27。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • 27. Thank you, Paul. The Slide #27 in our deck, we point to the fact that Lotemax right now, based on our best estimates, is a second half 2019 event. But once again, we're going to say, it's not a date-certain event.

    27。謝謝你,Paul。在我們簡報的投影片#27,我們指出 Lotemax 目前依據我們的最佳估計,將是2019年下半年的事件。但再次強調,我們會說,這不是一個確定日期的事件。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes. I'm going to just follow that up and, again, point you directly to Slide 27. The 3 products that you called out all were changed. When we change an assumption on -- with respect to these LOE assets, we typically highlight it in red. So all 3 are the ones you referenced changed. They're shown on Slide 27. Each one of those products, if you want to get a guesstimate or, actually, a pretty accurate estimate of that trailing 4 quarters revenue, all 4 are part of our top 10 products either by segment or overall, so you can draw your own conclusions from that.

    是的。我再補充一下,並且再次請你直接參考第27頁投影片。你點名的那3項產品都已經變更。當我們就這些LOE資產變更某項假設時,我們通常會用紅色標示。所以你提到的那3項都已經變更。它們都列在第27頁投影片上。這些產品中的每一項,如果你想粗估,或其實相當精準地估算其過去連續4個季度的營收,這4項都屬於我們按事業部或整體口徑的前十大產品之一,因此你可以自行從中得出結論。

  • Operator

    Operator

  • The next question will be from Gary Nachman with Bank of Montreal.

    下一個問題來自蒙特婁銀行(Bank of Montreal)的Gary Nachman。

  • Ann-Hunter Van Kirk - Associate

    Ann-Hunter Van Kirk - Associate

  • This is Ann-Hunter Van Kirk on for Gary. A couple of questions. If you could give us a better understanding of the gross to net accruals? And how that impacted 3Q overall? And also, you discussed your significant paydown this year. But with XIFAXAN in place, do you see a high probability that you'll be able to actually restructure the debt again and push out maturities even past 2021?

    我是代替Gary的Ann-Hunter Van Kirk。有幾個問題。你們能否讓我們更清楚了解毛額到淨額(gross-to-net)應計項目?以及它對第三季(3Q)整體的影響?另外,你們也談到今年大幅償還債務。但在XIFAXAN到位的情況下,你們是否認為很有可能再次重整債務,並把到期日延後到甚至超過2021年?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes, I'll be addressing the gross net. The reason why I spent probably more time on it than people would have liked on a call is, yes, it's an important driver for us. As I said, we started these initiatives back in 2017, and the kind of the way it works, it's worth reiterating is, until you start to see the actual results, meaning lesser deductions, gross to net, you kind of keep going along. But as you, in a period, see significant reductions in the actual process gross to net items associated with some of these branded products, that's when it forces you to look at your quarter-close accrual and true that accrual up based on the most recent experience. I called it out because it was a driver. I think the easiest example to follow along with is RELISTOR. RELISTOR's scripts were up strongly. However, we are up 88% year-over-year. That's a result of that kind of magnification of the improved gross to net in Q3 of '18 relative to Q3 of '17. That will normalize over time. I think you saw some of that across I called out within the GI, the Salix portfolio, and you saw some of that with respect to that certainly within the dermatology portfolio. I specifically pointed to the fact that I would not expect the results that we have in our medical derm portion of the Ortho Dermatologics segment to be at the sales level that you saw in Q3, that it would return to something akin to what you saw in the first couple of quarters of this year. Last thing on this because it's just I know we're going to get lots of question on it and I appreciate that, we'll do our best to answer, this goes against you too. We had UCERIS, which lost exclusivity in July. As those units start to fall off and you reevaluate your pipeline inventories, you start to take a look at gross to nets there. The gross to nets in that were dramatically worse than we would expect them to be in Q4 and going forward. That's a long-winded way of saying, if you look at the drop-off in UCERIS from Q2 to Q3, you'd say, wow, it really fell off. It's like, yes, a little bit of that is the other side of a true-up of gross to net accruals associated with that brand. And so a lot going on with respect to those quarter-close accruals. That's why we spend so much time on it.

    是的,我會說明毛額到淨額(gross-to-net)。我之所以在電話會議上花了可能比大家希望更多的時間談這件事,是因為,沒錯,這對我們而言是重要的驅動因素。如我所說,我們在2017年就開始推動這些措施,而其運作方式值得再重申一次:在你開始看到實際結果之前,也就是扣減項(deductions)變少、毛額到淨額改善之前,你基本上會持續推進。但當你在某一期間看到與部分品牌產品相關的實際流程中毛額到淨額項目出現顯著下降時,這就會迫使你在季度結帳時重新檢視應計,並依據最新經驗把該應計調整到位(true-up)。我特別提出來,因為它是一個驅動因素。我認為最容易理解的例子是RELISTOR。RELISTOR的處方量(scripts)強勁上升。然而,我們年增了88%。這是因為2018年第三季相較於2017年第三季,毛額到淨額改善在第三季被放大所致。這會隨時間正常化。我想你也在我提到的GI(腸胃)領域、Salix產品組合中看到一些類似情況,並且在皮膚科產品組合中也確實看到一些。我特別指出,我不預期我們在Ortho Dermatologics事業部的醫學皮膚科(medical derm)部分,其結果會維持在你在第三季看到的銷售水準;它會回到更接近今年前幾個季度的水準。最後再補充一點,因為我知道我們會收到很多相關問題,也感謝大家,我們會盡力回答,這也同樣適用於你。我們的UCERIS在7月失去獨家權。當這些單位開始下滑、你重新評估通路庫存(pipeline inventories)時,你就會開始檢視那裡的毛額到淨額。該產品的毛額到淨額比我們原先預期在第四季以及未來都要糟得多。換句話說,如果你看UCERIS從第二季到第三季的下滑,你會說,哇,真的掉很多。是的,其中一部分其實是與該品牌相關的毛額到淨額應計調整到位(true-up)的另一面。因此,季度結帳應計方面有很多事情同時在發生。這就是為什麼我們花這麼多時間談它。

  • Your question regarding the continuation of our efforts to deal with our cap structure. I think we found ourselves with the work we've done over the last, let's call it, 18 months in pretty good shape. I mean, we don't have any significant maturities going out through 2020. And so now we're starting to look -- as you saw, we announced and paid off $125 million of the debt due in 2021. So we're starting to turn our attention to the 2021 debt stack. I'd say, that is a process. As much progress as we've made, we just need to continue along with for the foreseeable future.

    你問到我們持續處理資本結構(cap structure)的努力。我認為,憑藉我們在過去大約18個月所做的工作,我們目前的狀況相當不錯。也就是說,我們在2020年之前沒有任何重大的到期債務。因此我們現在開始著手處理——如你所見,我們已宣布並償還了2021年到期的1.25億美元債務。所以我們開始把注意力轉向2021年的債務結構(debt stack)。我會說,這是一個過程。儘管我們已取得不少進展,但在可預見的未來仍需要持續推進。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • I'd add to what Paul said in that last point. I think Paul and Will have done an outstanding job in moving the debt stack out and giving us, what I always refer to as, freedom to operate so that we can grow our EBITDA, and that to me is really the most important way for us to think about what we're doing on a delevering point of view. But good work by Paul and the team on this.

    我補充Paul剛才最後那點。我認為Paul和Will在延後債務到期結構(debt stack)方面做得非常出色,並給了我們我常說的「營運自由度」(freedom to operate),讓我們能夠成長EBITDA;對我而言,這才是我們在去槓桿(delevering)角度思考我們所做事情的最重要方式。Paul和團隊在這方面做得很好。

  • Operator

    Operator

  • Next question will be from Umer Raffat with Evercore.

    下一個問題來自Evercore的Umer Raffat。

  • Umer Raffat - Senior MD & Senior Analyst of Equity Research

    Umer Raffat - Senior MD & Senior Analyst of Equity Research

  • Joe, first for you. So I noticed consensus models top line growing for Bausch going forward over the next several years, including next year. Is that how you understand the business to be, one. And then secondly, Paul you used the words "wicked good" on EBITDA, so I wanted to comb through that a little more. So Q4 EBITDA guidance is implying down, not just versus Q3, but versus Q2 as well based on the guidance. And you also hinted that the distribution strategy could have some impact. So that's really my question. What exactly is going on, on the inventory? Are there certain -- on the distribution channels, are you entering or exiting certain channels? Just to understand this dynamic because it sounds like it will be negative in Q4, but it will be positive next year and how that actually ends up tying into gross to net. Just wanted to clarify this whole thing.

    Joe,先問你。我注意到市場共識模型預期Bausch未來幾年(包括明年)營收(top line)會成長。第一,你對這個業務的理解也是如此嗎?第二,Paul你用「wicked good」來形容EBITDA,所以我想更仔細拆解一下。依照你們的指引,第四季EBITDA指引暗示下滑,不只是相較第三季,也相較第二季。你也暗示配銷策略可能會有一些影響。所以我的問題是:庫存到底發生了什麼事?在配銷通路方面,你們是否正在進入或退出某些通路?我想理解這個動態,因為聽起來第四季會是負面,但明年會轉為正面,以及這最終如何與毛額到淨額(gross-to-net)連動。只是想把整件事釐清。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Sure. I'll take the first part of the question. So on our growth comments, the best thing, I think, I can comment about in terms of how we are viewing our future is what we have said historically and what have come through our strategic plans is that, as we think about the growth in our business, we look -- we talked about a compound annual growth rate. What we have said previously on the top line is that across our Bausch health care business, we expect an annual CAGR growth approximately over any 3-year period of a 4% to 6% CAGR on the revenue side and on the EBITDA side is that 5% to 8%. I think that's probably what I'll stick with relative to what we've said historically and how we are modeling our business going forward. Obviously, there could always be variations quarter-to-quarter, year-to-year, but the annual approach that we're looking at is trying to grow that EBITDA by the 5% to 8% and grow the revenue somewhere in that 4% to 6%, depending on what happens in any given year. Paul, do you want to take that second part of the question?

    好的。我先回答問題的第一部分。關於我們對成長的評論,我認為就我們如何看待未來而言,我能說的最好方式是回到我們過去的說法以及我們的策略規劃所呈現的內容:當我們思考業務成長時,我們看的是複合年成長率(CAGR)。我們先前對營收端(top line)的說法是:在我們的Bausch醫療保健業務中,我們預期在任何3年期間,營收端的年CAGR約為4%到6%,而EBITDA端則為5%到8%。我想我會延續我們過去的說法,以及我們對未來業務建模的方式。當然,每季到每季、每年到每年都可能有波動,但我們採取的年度方法是,力求讓EBITDA成長5%到8%,並讓營收在4%到6%之間成長,視每一年實際情況而定。Paul,你要回答問題的第二部分嗎?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes, sure. And, Umer, I used the phrase wicked good because I'm a Sox fan, and I'm still really happy about how that series went. But much more seriously, $100 million, when you're contemplating at the adjusted EBITDA line, when you're executing a strategy that is definitionally going to reduce your expectation for the quarter by some $85 million at the adjusted EBITDA line, that's still pretty strong. We are fortunate that we have the opportunity to continue to execute on these core initiatives. When I said core cost optimization, revenue enhancement. What this is, is revenue enhancement. By executing on this, we expect to improve in a lasting way our gross to nets with respect to these products. Now what does this mean? Say, if you looked at Slides 50 and 51, we have, since I got here, reported our wholesale pipeline inventories so that everyone out there can follow along with what's going on. So there's no question about kind of where are we -- is -- results in a quarter or in any period, the results of any relative expansion or contraction of pipeline inventories. If you looked at that slide, what you'll see is over the course of 2018 year-to-date in our 4 segments that we point out on the branded pharma space, the only one -- I'm sorry, year-to-date, the derm is up a couple of months, 0.23 relative to the prior year-to-date period; the neuro business is down 0.22 months; the ophtha Rx is up 0.15; and the GI is down 0.08. But if you look at the balances at the end of the quarter, you see that they are generally down, and they have been trending down over the course of the last, call it, I don't know, 8 quarters. And so we are working to better align our supply chain with demand. And part of that is going to be reducing from, call it, circa 1.4 or 1.5 months supply out in the channel down to a number closer to a month. The cost of that, as again we estimate in 2018 and Q4 of '18, is circa $100 million of reduced revenue expectations. I think the returns are going to be, as I said on the call, I use the word unassailable. Anybody on this call, I think, would make this economic decision at this moment in time. The hard part about it is the optics are, yes, our revenue is going to be less in '18 and in Q4, and our adjusted EBITDA is going to be less in '18 and in Q4 than it could have been if we just kept doing what we had been doing before. This is one of those things where when Joe joined and sort of when I joined after him, there were a number of initiatives that we started way back when. And these things are -- they're not easy. They're -- I won't call them hard, but it's like, yes, they're -- we've been working on this for quite some time to get to the place where we can execute on this change and now is the time.

    是的,當然。而且,Umer,我用「wicked good」這個說法是因為我是紅襪隊球迷,而且我對那個系列賽的結果仍然非常開心。但更嚴肅地說,當你在考量調整後 EBITDA 這一行時,當你在執行一項按定義會在調整後 EBITDA 層面把你對本季的預期降低約 8,500 萬美元的策略時,1 億美元仍然相當強勁。我們很幸運能有機會持續推進這些核心舉措。我所說的核心成本最佳化、營收提升。而這件事就是營收提升。透過執行這項措施,我們預期能以持久的方式改善這些產品的 gross-to-net。那這代表什麼?比方說,如果你看第 50 與 51 張投影片,自從我來到這裡以來,我們一直揭露我們的批發通路管線庫存,讓外界每個人都能追蹤目前的狀況。因此,完全不會有疑問:某一季或任何期間的結果,在多大程度上是由管線庫存相對擴張或收縮所造成。如果你看那張投影片,你會看到在 2018 年年初至今、我們在品牌藥品領域所指出的 4 個事業部中,只有一個——抱歉,年初至今,皮膚科相較於前一年同期增加了幾個月,為 0.23;神經科業務下降 0.22 個月;眼科處方藥上升 0.15;GI 下降 0.08。但如果你看季末的餘額,你會看到它們整體而言是下降的,而且在過去大概——我不知道——8 個季度的期間一直呈下降趨勢。因此,我們正在努力讓供應鏈與需求更好地對齊。其中一部分將是把通路端大約 1.4 或 1.5 個月的供應量,降低到更接近 1 個月的水準。其成本,如同我們對 2018 年以及 2018 年第四季所估計的,約為 1 億美元的營收預期下調。我認為回報將會是——正如我在電話會議上所說,我用的詞是「無可撼動」。我想在座任何人,在此時此刻都會做出這個經濟決策。困難之處在於外界觀感:是的,我們在 2018 年以及第四季的營收會更少,而我們在 2018 年以及第四季的調整後 EBITDA 也會比如果我們只是延續先前做法時可能達到的水準更低。這是那種在 Joe 加入、以及我在他之後加入時,我們很早以前就啟動的一系列舉措之一。而這些事情——它們不容易。它們——我不會說很難,但就是,是的——我們為了走到能夠執行這項變更的階段已經努力了相當長一段時間,而現在就是時機。

  • Operator

    Operator

  • That question will be from David Amsellem with Piper Jaffray.

    下一個問題將由 Piper Jaffray 的 David Amsellem 提問。

  • David A. Amsellem - MD and Senior Research Analyst

    David A. Amsellem - MD and Senior Research Analyst

  • So I wanted to ask a sort of broader question about business developments and in-licensing. I mean, you've started to do deals that are leveraged commercial infrastructure, particularly in gastroenterology and maybe even over time primary care like the DOPTELET deal with Dova. So -- but I wanted to ask you this, I mean, given the state of the capital structure, how should we think about how aggressive you can be regarding the acquisition of products? And what kind of approaches you think you can take regarding accessing capital to bring in products? Are you looking at pipeline-related assets, particularly in GI to acquire or you're looking at ways to add more commercial-stage assets that leverage the infrastructure? Help us understand your thinking and particularly how you expect or how you can deploy capital to that end?

    我想問一個比較宏觀的問題,關於業務發展與引進授權(in-licensing)。我的意思是,你們已開始做一些能夠槓桿既有商業化基礎設施的交易,特別是在腸胃科領域,甚至隨著時間推進,可能也延伸到基層醫療,例如與 Dova 的 DOPTELET 交易。所以——但我想問的是,考量到資本結構的狀況,我們應該如何看待你們在產品收購方面能有多積極?以及在取得資金以引進產品方面,你們認為可以採取哪些方式?你們是在尋找與研發管線相關的資產、特別是 GI 領域可收購的標的,還是尋找能利用既有基礎設施、更多處於商業化階段的資產?請協助我們理解你們的想法,特別是你們預期或你們能如何為此目的配置資本?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • It's a great question, David. Thank you for the question. Relative to what we've talked about for the past couple of years now, we've been in the multi-year plan on transformation of this business. What we said, first and foremost, we had to do is focus on which therapeutic areas that we want to focus on and that, for us, was the ophthalmology or eye care business, the GI and the dermatology. Once we've accomplished that, it was then a question of figuring out where can we best invest behind those businesses. So for example, we've put in that primary care team that you mentioned and saw a great return on investment. But our long-term goal is very much to continue to develop products both internally or organically, but also through inorganic. What we've had a chance to talk about today is really just the transformation that we've been talking about where we can make some investments both on some products that are in addition to what we can do organically. I talked about a couple of them today. PLENVU is a product that we have license in and finally got a chance to launch this year. The LUCEMYRA that -- for us, fits perfectly with what we're doing on RELISTOR and talking about how oral RELISTOR helps the patients with opioid-induced constipation. The LUCEMYRA is just another perfect bolt-on for that product. The other one that we've talked about in the past was in our dermatology space, we developed an early-stage product from Kaken that's going to help us in the area of psoriasis. So look to see us continue to look at opportunities to grow both organically and through inorganic means. I will say for the near term, Paul and the team and the finance and treasury team has done a great job in resolving some of our debt issues, but we're probably not yet at a stage where you're going to see us go after a multibillion-dollar opportunities. But certainly, we can do the bolt-ons that are in the $100 million type range or a couple hundred million dollar range. Those will be the ones that we continue to look at. We think they make a lot of sense because they're strategically perfect fits for ophthalmology, GI and derm, where we think we have some great relationships and, importantly, some good intellectual know-how about what is important to those physicians and those patients. So certainly, we'll continue to look to do more bolt-ons, but order of magnitude under the $1 billion range is more likely than over the $1 billion range in the nearer term.

    這是個很好的問題,David。謝謝你的提問。就我們過去幾年所談的內容而言,我們一直在推動這項業務的多年轉型計畫。我們說過,首要之務是聚焦我們想要專注的治療領域;對我們而言,就是眼科或眼部照護業務、GI 與皮膚科。一旦完成這件事,接下來就是要釐清我們在哪些地方最適合加大投資以支持這些業務。例如,我們建立了你提到的那支基層醫療團隊,並看到了很好的投資報酬。但我們的長期目標非常明確:持續在內部或以有機方式開發產品,同時也透過非有機方式來發展。我們今天有機會談到的,其實就是我們一直在談的轉型:我們可以在一些產品上進行投資,這些投資是對我們有機成長能力的補充。我今天提到了其中幾個。PLENVU 是我們引進授權的一個產品,終於在今年有機會上市。LUCEMYRA——對我們而言——與我們在 RELISTOR 上所做的事情完全契合,也呼應我們談到口服 RELISTOR 如何幫助因鴉片類藥物引起便祕的患者。LUCEMYRA 只是對該產品另一個非常合適的補強(bolt-on)。另一個我們過去談過的是在皮膚科領域,我們從 Kaken 開發了一個早期階段產品,將在乾癬領域幫助我們。因此,請期待我們持續尋找同時透過有機與非有機方式成長的機會。我會說,就短期而言,Paul 與團隊、以及財務與資金管理團隊在解決我們部分債務問題上做得非常出色,但我們可能還沒到你會看到我們去追逐數十億美元等級機會的階段。但當然,我們可以做那種 1 億美元左右或數億美元規模的補強型交易。這些會是我們持續關注的標的。我們認為它們非常合理,因為在眼科、GI 與皮膚科方面,它們在策略上是完美契合;我們認為我們在這些領域擁有很好的關係,且更重要的是,我們對那些醫師與患者重視什麼有很好的專業理解。因此,我們肯定會持續尋求更多補強型交易,但在較近期內,規模低於 10 億美元的可能性會高於超過 10 億美元的。

  • Operator, next question?

    主持人,下一個問題?

  • Operator

    Operator

  • Sure, and that will be from Dana Flanders from Goldman Sachs.

    好的,下一位是來自高盛的 Dana Flanders。

  • Dana Carver Flanders - Research Analyst

    Dana Carver Flanders - Research Analyst

  • My first one here is, can you just speak to XIFAXAN in postoperative Crohn's and just, one, kind of the confidence jumping into the Phase III? I think the European data was not in the postoperative setting that you cited, and then two, maybe speak a little bit around how you're thinking about that market opportunity.

    我第一個問題是,你能否談談 XIFAXAN 在術後克隆氏症(Crohn's)方面的情況,以及第一,對於直接進入第三期試驗的信心來源是什麼?我認為你引用的歐洲數據並不是在術後情境下,第二,也請談談你們如何看待那個市場機會。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • So maybe just a little bit on the facts side, some of the things that we've been looking at here. First and foremost, we're delighted that we resolved the arbitration with Alfasigma. That gave us access to this investigational formulation of rifaximin. Specifically, it is an extended intestinal release formulation, so it has different release characteristics from the existing molecules. So we felt that was an important question on where it's going to deliver within the GI tract. So that would be the first point that this formulation is different from the existing formation. Relative to the opportunity, unfortunately, based on what we've researched, there are more than 750,000 Americans that have Crohn's disease and the majority of them, 75% of them, will eventually require surgery. Our belief is that in that postsurgical situation, postoperatively, that we believe rifaximin could be a very important adjunct to other therapies and other issues that these patients face. And we believe that based on the available data that exists that we could go forward, as I said, with a late-stage clinical program in this area. So we're excited about what the opportunity could mean to help these patients with the postoperative opportunity in Crohn's disease.

    所以也許先從事實面稍微補充一下,我們在這裡一直在看的幾件事。首先也是最重要的,我們很高興已經與 Alfasigma 解決了仲裁案。這讓我們得以取得這個利福昔明(rifaximin)的研究用劑型。具體而言,這是一種延長腸道釋放劑型,因此其釋放特性與現有分子不同。因此我們認為,一個重要問題在於它會在胃腸道內的哪個部位釋放並發揮作用。所以第一點是,這個劑型與現有劑型不同。就市場機會而言,不幸的是,根據我們的研究,美國有超過 75 萬名克隆氏症患者,其中多數(75%)最終將需要手術。我們相信在術後情境、也就是術後恢復期,利福昔明可能會成為其他治療的非常重要的輔助用藥,並有助於處理這些患者面臨的其他問題。而且我們相信,基於現有可得資料,我們可以如我所說,在這個領域推進一項後期臨床計畫。因此,我們對這個機會可能代表的意義感到振奮,因為它有望在克隆氏症的術後治療機會上幫助這些患者。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Okay. And then maybe just my quick follow-up. Just on the international segment, I know you mentioned last quarter you were taking steps to just improve the consistency of that business. Maybe just an update on where you are on that progress and if you're seeing early returns on some of the steps you're taking.

    好的。那我再快速追問一下。關於國際事業部,我知道你上季提到你們正在採取一些措施來提升該業務的一致性。能否更新一下目前進展到哪裡,以及你們是否已在所採取的一些措施上看到初步成效?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Sure, Dana. It's Paul to answer this one. I think that we called -- we did call it. I believe it was last quarter. It might have been first quarter. I think it was second quarter. Tom Appio, who runs our international group, has done a phenomenal job of reconfiguring his organization to be much more effective in our various geographies. And I would say, I think what I said or similar to what I said at Q2, some of the units -- some of the geographies are ahead of other geographies. And I think you could see it in my remarks. I think right now our business in Egypt, Amoun, is firing on all cylinders, doing really well. Our Latin American business is -- which is run out of our -- out of Mexico, is doing very well. And what we're seeing is the laggards are -- continue to be Eastern Europe and Russia. That's not to say that the team there is not doing the job, it's that the steps that Tom and his team have put in place, we just haven't seen the turn there yet. When we turn there, it will be a helper to [say] here as we go forward from a growth perspective. Clearly, the Russian and Eastern European units were the drag that kept that international pharma segment from being a grower. It was the only one that was flat.

    當然,Dana。這題由 Paul 來回答。我想我們確實提過——我們確實有提到。我相信是在上一季。也可能是第一季。我想是第二季。負責我們國際團隊的 Tom Appio,在重新配置其組織、讓其在各個地區更有效率方面做得非常出色。我會說,我想我在第二季所說的或類似的說法是:有些單位——有些地區——走在其他地區前面。我想你也可以從我的發言中看出來。我認為目前我們在埃及的業務 Amoun 正全速運轉,表現非常好。我們的拉丁美洲業務——由墨西哥負責營運——也做得非常好。而我們看到落後的部分——仍然是東歐與俄羅斯。這並不是說那裡的團隊沒有把工作做好,而是 Tom 與其團隊所推動的措施,我們還沒有在那裡看到轉折。一旦那裡出現轉折,從成長角度來看,將會成為我們往前推進的助力。很明顯,俄羅斯與東歐單位是拖累國際製藥事業部無法成長的因素。那是唯一持平的部分。

  • Operator

    Operator

  • Next question will be from Annabel Samimy with Stifel.

    下一個問題來自 Stifel 的 Annabel Samimy。

  • Annabel Eva Samimy - MD

    Annabel Eva Samimy - MD

  • So you seem to have stabilized dermatology this quarter. I'm trying to understand how much benefit was from the true-up in the accounting changes that were going on and how much is it from actual volume growth. And now that you have several new products starting to launch in this segment, what's the early reception been by payers given that this area of dermatology has been one of the favorites for reimbursement hurdles in the last few years?

    看起來你們本季已讓皮膚科業務趨於穩定。我想了解其中有多少助益來自會計變更所進行的調整(true-up),又有多少來自實際銷量成長。另外,既然你們在這個事業部有數個新產品開始上市,考量到皮膚科在過去幾年一直是報銷門檻較高的領域之一,付款方對這些產品的早期接受度如何?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes, I'll start, Joe, and you might want to jump in. On the medical derm side, as I said, volumes were -- continued to be down. We have the genericization of a couple of the strengths of Solodyn. You've got a number of things going on there, but here is the good news. The good news is that the steps as I pointed out earlier, it's a kind of a theme of the call. The improvements that we're seeing in the gross to nets are actual observed deductions that degrade gross to net sales. We're making progress. We're making particular progress in dermatology. So we are getting to -- certainly to the point where that legacy portfolio kind of the existing assets ought to perform better. Now how much of that was attributable to the true-up? I sort of called out and said if the sales in the medical derm part were $148 million in the quarter, and I said, it's going to back to something akin to what we saw in Q1 and Q2. That gives you an idea of the magnitude of the helper that the true-up -- or the accruals were in Q3. The good news is, as I said, part of the step-up what you see there is durable. It will continue on because you have lesser-observed deductions in gross to net. And so that's a helper to us as we go forward. So I'd say that we're getting to the point where we stabilize that portfolio and now we start to see ramps of the various products that we launched, that we launched SILIQ. SILIQ continues to ramp week to week to week. We launched ALTRENO just very recently. That's early days. We're hopeful that we'll be shortly launching BRYHALI. And then in the first part of next year, you add DUOBRII into that, and I think you can see that the future for dermatology looks like it will change.

    是的,我先說,Joe,你也可以補充。在醫療皮膚科(medical derm)方面,如我所說,銷量——仍然在下滑。Solodyn 的幾個規格已經面臨學名藥化。那裡有很多事情同時在發生,但好消息是這樣。好消息是,正如我先前指出的,這也是本次電話會議的一個主題。我們在「毛利到淨額」(gross-to-net)方面看到的改善,來自實際觀察到的扣減項目,這些扣減會侵蝕毛利到淨銷售額。我們正在取得進展。我們在皮膚科方面尤其取得了進展。因此我們正走向——確實走到一個階段,讓那個既有產品組合、也就是現有資產,應該能有更好的表現。那其中有多少可歸因於 true-up?我大致有點出來說,如果本季醫療皮膚科部分的銷售額是 1.48 億美元,我也說過,它會回到類似我們在第一季與第二季看到的水準。這讓你大概了解第三季 true-up——或應計項目(accruals)——所帶來助益的量級。好消息是,如我所說,你在那裡看到的部分提升是可持續的。它會持續下去,因為毛利到淨額中的實際扣減變少了。因此,這會在我們往前推進時成為助力。所以我會說,我們正接近讓那個產品組合穩定下來的階段,接著就會開始看到我們推出的各項產品逐步放量成長;我們已推出 SILIQ。SILIQ 持續以每週、每週、每週的節奏爬升。我們也在不久前剛推出 ALTRENO。那還是早期階段。我們希望不久後能推出 BRYHALI。然後在明年初,你再把 DUOBRII 加進來,我想你可以看到皮膚科的未來看起來將會改變。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • I think I'd add -- and Paul answered it very well. The only thing I'd add, to just give a little more specificity. The Retin-A Micro 0.06% and 0.08% combined, up 50% versus a year ago. We think that's, obviously, important. And we are getting good coverage, although I would say the gross to nets there are very high for us. On SILIQ, as I mentioned during the call, were up 65% just versus the sequential quarter. Also, our coverage in SILIQ is somewhere around that 77% commercial coverage, so we feel very good about that. The other part of what was happening in this business is looking at what happened with Solta. Solta was up approximately 15% in the quarter. So -- and that is not subject to a reimbursement environment. So on balance, I think we feel good that we're making a turn and -- but clearly, as I mentioned in the call, the future of our dermatology business will be new products, new products, new products. And that's really what's going to drive the long-term turnaround in our dermatology business.

    我想我會補充——而且 Paul 已經回答得很好。我唯一要補充的是,提供更具體一點的數字。Retin-A Micro 0.06% 與 0.08% 合計,較去年同期成長 50%。我們認為這顯然很重要。而且我們獲得了良好的給付覆蓋,雖然我會說,我們在那裡的毛利到淨額扣減比例仍然非常高。至於 SILIQ,如我在電話會議中提到的,僅較上一季(環比)就成長了 65%。另外,我們在 SILIQ 的覆蓋率大約在 77% 的商業保險覆蓋,因此我們對此感到非常滿意。這項業務中另一個正在發生的部分,是看看 Solta 的表現。Solta 本季約成長 15%。所以——而且那不受報銷環境影響。因此整體而言,我想我們對正在出現轉折感到樂觀——但很明顯,如我在電話會議中提到的,我們皮膚科業務的未來將是新產品、新產品、新產品。而這才是真正會推動我們皮膚科業務長期翻轉的動力。

  • Annabel Eva Samimy - MD

    Annabel Eva Samimy - MD

  • Okay. So if I could just ask a quick follow-up. So you have a pretty decent improving position from a business and a core perspective. Can you maybe now consider a more aggressive capital restructuring? We get a lot of questions about equity for capital restructuring. And so how do you feel about that given your current position?

    好的。那如果我可以再快速追問一下。你們從業務面與核心基本面來看,處於相當不錯、且正在改善的位置。那你們現在是否可以考慮更積極的資本結構重整?我們收到很多關於以股權進行資本重整的問題。因此,基於你們目前的狀況,你們對此有何看法?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Maybe I'll start, but, Paul, feel free to add anything. I think what I tried to say before during a previous question is that, I think, Paul and the team just have done an outstanding job of stabilizing our debt situation. They've given us freedom to operate relative to -- till 2021 and beyond. What we've got to do, really, for us is to grow our EBITDA. We think that's the best way for us to delever as we grow revenue, grow EBITDA. So clearly, as we're looking at it right now that our best long-term suggestion here or solution for us, grow EBITDA and that by growing the EBITDA, we'll naturally delever, especially right now, as we believe the stock is undervalued relative to where we believe it should be. So I think our long-term solution is still to keep all options on the table, but over the long term we want to make sure that we focus on the freedom to operate and growing our EBITDA in the long term.

    也許我先開始,不過,Paul,你也可以隨時補充。我想我之前在上一個問題時試著表達的是,我認為Paul和團隊在穩定我們的債務狀況方面做得非常出色。他們讓我們在營運上有了自由度——一直到2021年及之後。我們真正需要做的,是提升我們的EBITDA。我們認為,隨著營收成長、EBITDA成長,這是我們去槓桿的最佳方式。所以很明顯,就我們目前的觀察,我們最佳的長期建議或解決方案是提升EBITDA;而透過提升EBITDA,我們會自然地去槓桿,尤其是在我們認為股價相對於其應有水準被低估的當下。因此我認為我們的長期解方仍是保留所有選項,但從長期來看,我們要確保聚焦於營運自由度,並在長期推動EBITDA成長。

  • Operator

    Operator

  • Our final question today will come from Louise Chen with Cantor.

    我們今天最後一個問題將由Cantor的Louise Chen提出。

  • Louise Alesandra Chen - Senior Research Analyst & MD

    Louise Alesandra Chen - Senior Research Analyst & MD

  • So my first question is with respect to the gross to net improvements. Are there any other products or areas where you see that coming up in the future? And then can you remind us where you are with your Significant Seven? How they're tracking relative to your expectations? And then lastly, anything that you could give us on either debt paydown or obligations for 2019? Even if it's just qualitative would be helpful.

    所以我的第一個問題是關於gross-to-net(毛額到淨額)的改善。未來是否還有其他產品或領域,你們也看到會出現這樣的改善?另外,你能否提醒我們「Significant Seven(重要七項)」目前的進度?它們相對於你們的預期表現如何?最後,關於2019年的債務償還或相關義務,有沒有任何可以提供的資訊?即使只是定性的說明也會很有幫助。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • I'll start with the gross to nets. I think you're seeing a fairly significant change in Q3 '18 relative to '17, and even on a sequential basis, if you look at it that way. I mean, are there other opportunities? Sure. I mean, we continue to look at each one of our products. I'll keep calling out the revenue enhancement -- part of our core program is designed for us to look and be smarter about the programs that we use to enable patients to access -- have access to our products. So the work is never done. But I think you're seeing a fairly significant improvement here year-to-date 2018. More to come for sure, but I'm not sure you're going to see it of the magnitude that you saw here in year-to-date '18.

    我先從gross-to-net談起。我想你看到的是,2018年第三季相較於2017年有相當顯著的變化;即便以序列(逐季)角度來看也是如此。我是說,還有其他機會嗎?當然有。我們持續檢視旗下每一項產品。我會持續強調營收提升——我們核心計畫的一部分,就是要讓我們更聰明地檢視我們用來協助病患取得——能夠取得我們產品的各項方案。所以這項工作永遠沒有完成的一天。但我認為你在2018年迄今確實看到相當顯著的改善。未來肯定還會有更多,但我不確定你會再看到像2018年迄今這樣幅度的改善。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Yes. Maybe the only thing I would add to the second part of your question on the Significant Seven is we're very pleased with the progress we're making. If you just think about RELISTOR, for example RELISTOR oral, which is one of the Significant Seven, that product this year is up 88% year-to-date. That's not just the quarter, that's the full year. 88% growth in oral RELISTOR, we think, obviously, is a very important achievement. If you look at -- listen to some of comments I made on Vyzulta. Vyzulta this quarter, up 20% versus the previous quarter, so I -- sequential quarter. So that, we feel, is very good. AQUALOX just launched in Japan. DUOBRII we've got it resubmitted for February PDUFA date -- February 15. SILIQ, I made a mention, it was up 65% TRx versus the second quarter. LUMIFY, already is the #2 product in the category, the #1 recommended physician product. And BRYHALI, which we expect to get approval very, very soon. So we're excited. We think we've made good progress. First and foremost, the products are approved. And then secondarily, as we think about where they're going, we're seeing some good statistics relative to the overall numbers that give us optimism for the future.

    是的。也許我對你第二部分、關於「Significant Seven」的問題,唯一要補充的是:我們對目前取得的進展非常滿意。如果你以RELISTOR為例,例如RELISTOR口服劑型,它是「Significant Seven」之一,該產品今年迄今成長了88%。這不只是單一季度,而是全年迄今。口服RELISTOR成長88%,我們認為顯然是一項非常重要的成果。如果你看——聽我對Vyzulta的一些評論。Vyzulta本季較上一季成長20%,所以我——以逐季來看。因此我們覺得表現非常好。AQUALOX剛在日本上市。DUOBRII我們已重新送件,PDUFA日期在2月——2月15日。SILIQ我也提到過,它的TRx相較第二季成長65%。LUMIFY已經是該類別的第2大產品,也是醫師推薦度第1的產品。以及BRYHALI,我們預期很快、非常非常快就會獲得核准。所以我們很振奮。我們認為已取得良好進展。首先也是最重要的是,這些產品已獲核准。其次,當我們思考它們未來的走向時,我們看到一些相對於整體數據的良好統計表現,讓我們對未來保持樂觀。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Sorry, Louise, I'm going to come back in and just -- I stopped talking and then I realized there's one more point I wanted to make on that gross to net because you had asked about the prospects for the future. I think first, it's helpful to frame it. If you think about the magnitude of the impact of the changes that we've been making to these programs, where you see it most in terms of improvement in gross to net is in derm. That's why you see the impact that you see on our Q3 quarter results, second in GI and then third in neuro. So that just help you calibrate. There are opportunities across any brand where we have programs to assist in patients being able to access our products or get access to our products and so it's -- the biggest impact was certainly in derm, second GI, third neuro.

    抱歉,Louise,我再補充一下——我剛剛停下來後才想到,關於gross-to-net還有一點想說,因為你問到未來的展望。我想先把框架說清楚會有幫助。如果你想想我們對這些方案所做調整的影響幅度,你在gross-to-net改善上看到最明顯的,是在皮膚科(derm)。這也是為什麼你會在我們第三季的季度結果中看到那樣的影響;其次是腸胃科(GI),第三是神經科(neuro)。這樣可以幫助你校準理解。只要是在任何品牌上我們有用來協助病患能夠取得我們產品、或獲得我們產品的方案,就都有機會——而最大的影響確實是在皮膚科,其次GI,第三neuro。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Louise, I don't think we can give you exact answer on the 2019. But, Paul, is there anything further you want to add about -- in terms of our approximation of what we said this year about paying down our debt being our most important priority?

    Louise,我想我們無法就2019年給你精確的答案。不過,Paul,關於——就我們今年所說「償還債務是我們最重要的優先事項」這點,你是否還想補充我們大致的看法?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Sure. I mean, I called it out in my prepared remarks in that we continue to prioritize the use of cash flow to reduce debt. And as you've seen most recently, now we're prioritizing and looking at the closest-in debt stack, which is in 2021. We have, on average, expect to produce cash flow from operations in the low $400 million range, and I think that we are generally on track with that in 2018 year-to-date, and I would expect that, that will continue on. Just to be real clear, when you talk about cash from ops, that's a pure GAAP measure. And so that represents the cash that would then be available to do such things as CapEx, certainly to pay for any non-GAAP items that we call out like settlements of legal liabilities and things like that and for any restructurings. But that would leave a fair chunk of dough available to continue to reduce debt.

    當然。我的事先準備講稿中已提到,我們仍然把運用現金流來降低負債列為優先事項。而如你最近所見,我們現在正優先處理並聚焦於最接近到期的債務結構,也就是2021年到期的部分。我們平均預期營運活動產生的現金流約在4億美元出頭的區間,我認為2018年迄今整體也大致符合這個軌跡,並且我預期這種情況會持續。再說清楚一點,當你談到營運現金流時,那是純粹的GAAP衡量指標。因此,那代表可用於資本支出(CapEx)的現金,當然也可用來支付我們所提及的任何非GAAP項目,例如法律責任和解金等,以及任何重整費用。但即便如此,仍會留下相當可觀的一筆資金,可用於持續降低負債。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Everyone, thank you very much for joining today, and a special thank you to all 21,000 Bausch health care team members for the great efforts in what we think is a very exciting transformation and what we always believe is the turnaround opportunity of a lifetime. Thank you all for joining us today.

    各位,非常感謝今天的參與;也特別感謝我們21,000位Bausch醫療保健團隊成員的卓越努力。我們認為這是一場非常令人振奮的轉型,也一直相信這是千載難逢的翻身機會。感謝各位今天與會。

  • Operator

    Operator

  • The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.

    本次電話會議到此結束。感謝您參加今天的簡報。您現在可以掛線。